US5112868A
(en)
*
|
1988-05-19 |
1992-05-12 |
Warner-Lambert Company |
Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues having cyclooxygenase and 5-lipoxygenase inhibition
|
US4943587A
(en)
*
|
1988-05-19 |
1990-07-24 |
Warner-Lambert Company |
Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues and their use for cyclooxygenase and 5-lipoxygenase inhibition
|
US5068251A
(en)
*
|
1988-12-16 |
1991-11-26 |
Abbott Laboratories |
Lipoxygenase inhibiting compounds
|
US5212189A
(en)
*
|
1991-12-17 |
1993-05-18 |
Warner-Lambert Company |
Thiadiazole or oxadiazole analogs of fenamic acids containing substituted hydroxamate side chains as antiinflammatory agents
|
US6096753A
(en)
*
|
1996-12-05 |
2000-08-01 |
Amgen Inc. |
Substituted pyrimidinone and pyridone compounds and methods of use
|
US6410729B1
(en)
|
1996-12-05 |
2002-06-25 |
Amgen Inc. |
Substituted pyrimidine compounds and methods of use
|
US6022884A
(en)
*
|
1997-11-07 |
2000-02-08 |
Amgen Inc. |
Substituted pyridine compounds and methods of use
|
US6107291A
(en)
*
|
1997-12-19 |
2000-08-22 |
Amgen Inc. |
Azepine or larger medium ring derivatives and methods of use
|
US6174901B1
(en)
|
1998-12-18 |
2001-01-16 |
Amgen Inc. |
Substituted pyridine and pyridazine compounds and methods of use
|
US6335329B1
(en)
|
1997-12-19 |
2002-01-01 |
Amgen Inc. |
Carboxylic acid substituted heterocycles, derivatives thereof and methods of use
|
US6187777B1
(en)
|
1998-02-06 |
2001-02-13 |
Amgen Inc. |
Compounds and methods which modulate feeding behavior and related diseases
|
US6514964B1
(en)
|
1999-09-27 |
2003-02-04 |
Amgen Inc. |
Fused cycloheptane and fused azacycloheptane compounds and their methods of use
|
US6849639B2
(en)
|
1999-12-14 |
2005-02-01 |
Amgen Inc. |
Integrin inhibitors and their methods of use
|
US6429223B1
(en)
*
|
2000-06-23 |
2002-08-06 |
Medinox, Inc. |
Modified forms of pharmacologically active agents and uses therefor
|
US6921762B2
(en)
|
2001-11-16 |
2005-07-26 |
Amgen Inc. |
Substituted indolizine-like compounds and methods of use
|
AU2003247425B2
(en)
|
2002-05-22 |
2007-03-08 |
Amgen Inc. |
Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
|
US7176322B2
(en)
|
2002-05-23 |
2007-02-13 |
Amgen Inc. |
Calcium receptor modulating agents
|
US6908935B2
(en)
|
2002-05-23 |
2005-06-21 |
Amgen Inc. |
Calcium receptor modulating agents
|
CA2493667C
(en)
|
2002-08-08 |
2010-04-27 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
US7504396B2
(en)
|
2003-06-24 |
2009-03-17 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
US7442698B2
(en)
|
2003-07-24 |
2008-10-28 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
US7582631B2
(en)
|
2004-01-14 |
2009-09-01 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
US7429616B2
(en)
|
2005-07-15 |
2008-09-30 |
Board Of Regents, University Of Texas System |
Synthesis and complete stereochemical assignment of psymberin/irciniastatin for use as antitumor compounds
|
US7754717B2
(en)
|
2005-08-15 |
2010-07-13 |
Amgen Inc. |
Bis-aryl amide compounds and methods of use
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
CA2644783A1
(en)
|
2006-03-29 |
2007-10-18 |
Novartis Ag |
Selective hydroxamate based mmp inhibitors
|
AU2007265475B2
(en)
|
2006-06-26 |
2010-08-19 |
Amgen Inc. |
Methods for treating atherosclerosis
|
CA2656535C
(en)
|
2006-07-14 |
2011-08-23 |
Amgen Inc. |
Alkyne-substituted pyridone compounds and methods of use
|
ATE469144T1
(de)
|
2006-07-20 |
2010-06-15 |
Amgen Inc |
Substituierte pyridonverbindungen und anwendungsverfahren
|
JP5042311B2
(ja)
|
2006-07-20 |
2012-10-03 |
ノバルティス アーゲー |
Cetp阻害剤としてのアミノピペリジン誘導体
|
AU2007275683B2
(en)
|
2006-07-20 |
2012-05-10 |
Amgen Inc. |
Di-amino-substituted heterocyclic compounds and methods of use
|
JP5527761B2
(ja)
|
2007-03-23 |
2014-06-25 |
アムジエン・インコーポレーテツド |
複素環化合物およびそれの使用
|
CN101910150B
(zh)
|
2007-11-05 |
2013-09-18 |
诺瓦提斯公司 |
作为cetp抑制剂、可用于治疗疾病如高脂血症或动脉硬化的4-苄基氨基-1-羧基酰基哌啶衍生物
|
ES2375527T3
(es)
|
2007-12-03 |
2012-03-01 |
Novartis Ag |
Derivados 1,2-disustituidos-4-bencilamino-pirrolidina como inhibidores cetp útiles para el tratamiento de enfermedades tales como hiperlipidemia o arteriosclerosis.
|
US8222424B2
(en)
|
2008-03-24 |
2012-07-17 |
Novartis Ag |
Arylsulfonamide-based matrix metalloprotease inhibitors
|
AU2009333214B2
(en)
|
2008-12-17 |
2013-09-26 |
Amgen Inc. |
Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors
|
WO2010075869A1
(en)
|
2008-12-30 |
2010-07-08 |
European Molecular Biology Laboratory (Embl) |
Toluidine sulfonamides and their use
|
WO2010085968A1
(en)
|
2008-12-30 |
2010-08-05 |
European Molecular Biology Laboratory (Embl) |
Toluidine sulfonamides and their use as hif-inhibitors
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
PE20120403A1
(es)
|
2009-05-15 |
2012-05-03 |
Novartis Ag |
Aril-piridinas como inhibidoras de sintasa de aldosterona
|
ES2602826T3
(es)
|
2009-05-28 |
2017-02-22 |
Novartis Ag |
Derivados aminobutíricos sustituidos como inhibidores de neprilisina
|
CN102448928B
(zh)
|
2009-05-28 |
2014-10-01 |
诺华股份有限公司 |
作为中性溶酶(neprilysin)抑制剂的取代的氨基丁酸衍生物
|
EP2445898A2
(en)
|
2009-06-25 |
2012-05-02 |
Amgen, Inc |
4h-pyrido[1,2-a]pyrimidin-4-one derivatives as pi3k inhibitors
|
EA201270051A1
(ru)
|
2009-06-25 |
2012-05-30 |
Амген Инк. |
Гетероциклические соединения и их применения
|
AR077267A1
(es)
|
2009-06-25 |
2011-08-17 |
Amgen Inc |
Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
|
CA2765819A1
(en)
|
2009-06-25 |
2010-12-29 |
Amgen Inc. |
Heterocyclic compounds and their uses as inhibitors of pi3 k activity
|
AR077328A1
(es)
|
2009-07-24 |
2011-08-17 |
Novartis Ag |
Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
|
EA201200321A1
(ru)
|
2009-08-26 |
2012-09-28 |
Новартис Аг |
Тетразамещенные гетероарильные соединения и их применение в качестве модуляторов mdm2 и/или mdm4
|
JP2013503903A
(ja)
|
2009-09-03 |
2013-02-04 |
アラーガン インコーポレイテッド |
チロシンキナーゼモジュレーターとしての化合物
|
US9340555B2
(en)
|
2009-09-03 |
2016-05-17 |
Allergan, Inc. |
Compounds as tyrosine kinase modulators
|
WO2011026911A1
(en)
|
2009-09-04 |
2011-03-10 |
Novartis Ag |
Bipyridines useful for the treatment of proliferative diseases
|
US20120165306A1
(en)
|
2009-09-04 |
2012-06-28 |
Barsanti Paul A |
Pyrazinylpyridines useful for the treatment of proliferative diseases
|
CN102498107A
(zh)
|
2009-09-04 |
2012-06-13 |
诺瓦提斯公司 |
作为激酶抑制剂的杂芳基化合物
|
AR078770A1
(es)
|
2009-10-27 |
2011-11-30 |
Elara Pharmaceuticals Gmbh |
Derivados de dihidrobenzo oxacinas y tiazinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades inflamatorias e hiperproliferativas.
|
EP2501678B1
(en)
|
2009-11-17 |
2015-09-23 |
Novartis AG |
Aryl-pyridine derivatives as aldosterone synthase inhibitors
|
JO2967B1
(en)
|
2009-11-20 |
2016-03-15 |
نوفارتس ايه جي |
Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
|
CN102666535B
(zh)
|
2009-11-30 |
2015-02-25 |
诺华股份有限公司 |
作为醛固酮合酶抑制剂的咪唑衍生物
|
JP2013514989A
(ja)
|
2009-12-18 |
2013-05-02 |
アムジエン・インコーポレーテツド |
複素環式化合物およびその使用法
|
WO2011073316A1
(en)
|
2009-12-18 |
2011-06-23 |
Novartis Ag |
4-aryl-butane-1,3-diamides
|
WO2011076747A1
(en)
|
2009-12-21 |
2011-06-30 |
Novartis Ag |
Diaza-spiro[5.5]undecanes as orexin receptor antagonists
|
EP2516437B1
(en)
|
2009-12-21 |
2014-01-29 |
Novartis AG |
Disubstituted heteroaryl-fused pyridines
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
EP2531510B1
(en)
|
2010-02-01 |
2014-07-23 |
Novartis AG |
Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
|
WO2011092293A2
(en)
|
2010-02-01 |
2011-08-04 |
Novartis Ag |
Cyclohexyl amide derivatives as crf receptor antagonists
|
US8791100B2
(en)
|
2010-02-02 |
2014-07-29 |
Novartis Ag |
Aryl benzylamine compounds
|
US8835444B2
(en)
|
2010-02-02 |
2014-09-16 |
Novartis Ag |
Cyclohexyl amide derivatives as CRF receptor antagonists
|
UY33226A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
UY33304A
(es)
|
2010-04-02 |
2011-10-31 |
Amgen Inc |
Compuestos heterocíclicos y sus usos
|
US8324239B2
(en)
|
2010-04-21 |
2012-12-04 |
Novartis Ag |
Furopyridine compounds and uses thereof
|
EP2569302A1
(en)
|
2010-05-13 |
2013-03-20 |
Amgen, Inc |
Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
|
CA2800578A1
(en)
|
2010-05-13 |
2011-11-17 |
Amgen Inc. |
Nitrogen-heterocyclic compounds as phosphodiesterase 10 inhibitors
|
JP2013526537A
(ja)
|
2010-05-13 |
2013-06-24 |
アムジエン・インコーポレーテツド |
Pde10阻害剤としてのヘテロアリールオキシカルボシクリル化合物
|
AU2011253057B2
(en)
|
2010-05-13 |
2014-11-20 |
Amgen Inc. |
Nitrogen heterocyclic compounds useful as PDE10 inhibitors
|
WO2011157787A1
(en)
|
2010-06-17 |
2011-12-22 |
Novartis Ag |
Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
WO2011157793A1
(en)
|
2010-06-17 |
2011-12-22 |
Novartis Ag |
Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
UY33469A
(es)
|
2010-06-29 |
2012-01-31 |
Irm Llc Y Novartis Ag |
Composiciones y metodos para modular la via de señalizacion de wnt
|
AU2011272857A1
(en)
|
2010-06-30 |
2013-01-10 |
Amgen Inc. |
Quinolines as P13K inhibitors
|
MX2012015147A
(es)
|
2010-06-30 |
2013-05-01 |
Amgen Inc |
Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.
|
CA2803620A1
(en)
|
2010-06-30 |
2012-01-05 |
Amgen Inc. |
Heterocyclic compounds and their uses
|
WO2012003262A1
(en)
|
2010-07-01 |
2012-01-05 |
Amgen Inc. |
Heterocyclic compounds and their use as inhibitors of pi3k activity
|
AU2011272853A1
(en)
|
2010-07-01 |
2013-01-10 |
Amgen Inc. |
Heterocyclic compounds and their use as inhibitors of PI3K activity
|
AU2011272850A1
(en)
|
2010-07-02 |
2013-01-10 |
Amgen Inc. |
Heterocyclic compounds and their use as inhibitors of PI3K activity
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
US20120302558A1
(en)
|
2010-07-13 |
2012-11-29 |
Sangamesh Badiger |
Oxazine derivatives and their use in the treatment of neurological disorders
|
JP5781159B2
(ja)
|
2010-07-14 |
2015-09-16 |
ノバルティス アーゲー |
Ip受容体アゴニストヘテロ環式化合物
|
EP2595983A1
(en)
|
2010-07-22 |
2013-05-29 |
Novartis AG |
2,3,5-trisubstituted thiophene compounds and uses thereof
|
US9290485B2
(en)
|
2010-08-04 |
2016-03-22 |
Novartis Ag |
N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
|
RS54544B1
(en)
|
2010-09-13 |
2016-06-30 |
Novartis Ag |
Triazine-oxadiazoles
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
DK2619208T3
(en)
|
2010-09-20 |
2017-01-30 |
Ironwood Pharmaceuticals Inc |
IMIDAZOTRIAZINON COMPOUNDS
|
US20120101110A1
(en)
|
2010-10-26 |
2012-04-26 |
Sangamesh Badiger |
Diaza-spiro[5.5]undecanes
|
JP2013541591A
(ja)
|
2010-11-04 |
2013-11-14 |
アムジエン・インコーポレーテツド |
複素環化合物およびそれらの使用
|
US8877815B2
(en)
|
2010-11-16 |
2014-11-04 |
Novartis Ag |
Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
|
US8673974B2
(en)
|
2010-11-16 |
2014-03-18 |
Novartis Ag |
Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
|
US8993631B2
(en)
|
2010-11-16 |
2015-03-31 |
Novartis Ag |
Method of treating contrast-induced nephropathy
|
US8765768B2
(en)
|
2010-11-17 |
2014-07-01 |
Amgen Inc. |
Heterocyclic compounds and their uses
|
JP2014500277A
(ja)
|
2010-12-09 |
2014-01-09 |
アムジエン・インコーポレーテツド |
Pim阻害剤としての二環式化合物
|
CU24152B1
(es)
|
2010-12-20 |
2016-02-29 |
Irm Llc |
1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
|
WO2012087520A1
(en)
|
2010-12-20 |
2012-06-28 |
Irm Llc |
Compositions and methods for modulating farnesoid x receptors
|
JP2014500319A
(ja)
|
2010-12-20 |
2014-01-09 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
ファルネソイドx受容体を調節するための組成物および方法
|
WO2012087784A1
(en)
|
2010-12-23 |
2012-06-28 |
Amgen Inc. |
Heterocyclic compounds and their uses
|
SG191844A1
(en)
|
2011-01-04 |
2013-08-30 |
Novartis Ag |
Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
|
CA2824493A1
(en)
|
2011-01-13 |
2012-07-19 |
Novartis Ag |
Bace-2 inhibitors for the treatment of metabolic disorders
|
WO2012101063A1
(en)
|
2011-01-28 |
2012-08-02 |
Novartis Ag |
N-acyl pyridine biaryl compounds and their uses
|
WO2012101064A1
(en)
|
2011-01-28 |
2012-08-02 |
Novartis Ag |
N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
|
WO2012101066A1
(en)
|
2011-01-28 |
2012-08-02 |
Novartis Ag |
Pyridine biaryl amine compounds and their uses
|
WO2012101065A2
(en)
|
2011-01-28 |
2012-08-02 |
Novartis Ag |
Pyrimidine biaryl amine compounds and their uses
|
GB201103578D0
(en)
|
2011-03-02 |
2011-04-13 |
Sabrepharm Ltd |
Dipyridinium derivatives
|
AU2012230890A1
(en)
|
2011-03-22 |
2013-09-26 |
Amgen Inc. |
Azole compounds as Pim inhibitors
|
WO2012130306A1
(en)
|
2011-03-30 |
2012-10-04 |
Elara Pharmaceuticals Gmbh |
Bicyclic 2,3-dihyrdobenzazine compounds for use in therapy
|
WO2012130314A1
(en)
|
2011-03-31 |
2012-10-04 |
Elara Pharmaceuticals Gmbh |
Composition comprising docetaxel
|
WO2012130322A1
(en)
|
2011-03-31 |
2012-10-04 |
Elara Pharmaceuticals Gmbh |
Imidazo [1,2-a]pyridine compounds for use in therapy
|
WO2012138648A1
(en)
|
2011-04-06 |
2012-10-11 |
Irm Llc |
Compositions and methods for modulating lpa receptors
|
EP2702063A1
(en)
|
2011-04-29 |
2014-03-05 |
Amgen Inc. |
Bicyclic pyridazine compounds as pim inhibitors
|
PH12013502611A1
(en)
|
2011-06-24 |
2014-04-28 |
Amgen Inc |
Trpm8 antagonists and their use in treatments
|
US8778941B2
(en)
|
2011-06-24 |
2014-07-15 |
Amgen Inc. |
TRPM8 antagonists and their use in treatments
|
US8846656B2
(en)
|
2011-07-22 |
2014-09-30 |
Novartis Ag |
Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
|
EP2768813A1
(en)
|
2011-10-21 |
2014-08-27 |
Novartis AG |
Quinazoline derivatives as pi3k modulators
|
EP2802582A1
(en)
|
2012-01-13 |
2014-11-19 |
Novartis AG |
Fused dihydropyrido [2,3 -b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
|
EP2802581A1
(en)
|
2012-01-13 |
2014-11-19 |
Novartis AG |
7,8- dihydropyrido [3, 4 - b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
|
CN104053659B
(zh)
|
2012-01-13 |
2016-11-09 |
诺华股份有限公司 |
用于治疗肺动脉高压(pah)及相关病症的作为ip 受体激动剂的稠合的吡咯类
|
US9115129B2
(en)
|
2012-01-13 |
2015-08-25 |
Novartis Ag |
Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
|
US20150005311A1
(en)
|
2012-01-13 |
2015-01-01 |
Novartis Ag |
IP receptor agonist heterocyclic compounds
|
WO2013130660A1
(en)
|
2012-02-28 |
2013-09-06 |
Amgen Inc. |
Amides as pim inhibitors
|
TW201348231A
(zh)
|
2012-02-29 |
2013-12-01 |
Amgen Inc |
雜雙環化合物
|
HK1206726A1
(en)
|
2012-03-19 |
2016-01-15 |
Ironwood Pharmaceuticals, Inc. |
Imidazotriazinone compounds
|
PE20142457A1
(es)
|
2012-04-04 |
2015-02-07 |
Amgen Inc |
Compuestos heterociclicos y sus usos
|
AU2013255470B2
(en)
|
2012-05-04 |
2015-09-17 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
US20150152083A1
(en)
|
2012-06-06 |
2015-06-04 |
Irm Llc, A Delaware Limited Liability Company |
Compounds and Compositions for Modulating EGFR Activity
|
JO3300B1
(ar)
|
2012-06-06 |
2018-09-16 |
Novartis Ag |
مركبات وتركيبات لتعديل نشاط egfr
|
AR091436A1
(es)
|
2012-06-14 |
2015-02-04 |
Amgen Inc |
Compuestos de azetidina y piperidina utiles como inhibidores de pde10
|
BR112014031375A2
(pt)
|
2012-06-20 |
2017-06-27 |
Novartis Ag |
moduladores da série de reação complementar e usos dos mesmos
|
ES2710491T3
(es)
|
2012-06-28 |
2019-04-25 |
Novartis Ag |
Moduladores de la vía del complemento y sus usos
|
JP6209605B2
(ja)
|
2012-06-28 |
2017-10-04 |
ノバルティス アーゲー |
ピロリジン誘導体、および補体経路調節因子としてのその使用
|
JP6154897B2
(ja)
|
2012-06-28 |
2017-06-28 |
ノバルティス アーゲー |
ピロリジン誘導体、および補体経路調節因子としてのその使用
|
EA201590118A1
(ru)
|
2012-06-28 |
2015-04-30 |
Новартис Аг |
Производные пирролидина и их применение в качестве модуляторов пути активации комплемента
|
WO2014002058A2
(en)
|
2012-06-28 |
2014-01-03 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
CN104619698B
(zh)
|
2012-06-28 |
2016-08-31 |
诺华股份有限公司 |
吡咯烷衍生物及其作为补体途径调节剂的用途
|
WO2014009833A2
(en)
|
2012-07-12 |
2014-01-16 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
WO2014022752A1
(en)
|
2012-08-03 |
2014-02-06 |
Amgen Inc. |
Macrocycles as pim inhibitors
|
WO2014023329A1
(en)
|
2012-08-06 |
2014-02-13 |
Life And Brain Gmbh |
Niclosamide and its derivatives for use in the treatment of solid tumors
|
EP2895462A1
(en)
|
2012-09-13 |
2015-07-22 |
Baden-Württemberg Stiftung gGmbH |
Specific inhibitors of protein p21 as therapeutic agents
|
CN105189500A
(zh)
|
2013-02-13 |
2015-12-23 |
诺华股份有限公司 |
Ip受体激动剂杂环化合物
|
BR112015019369A2
(pt)
|
2013-02-14 |
2017-07-18 |
Novartis Ag |
derivados de ácido bisfenil butanóico substituídos como inibidores de nep (endopeptidase neutra)
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
US20160178610A1
(en)
|
2013-08-07 |
2016-06-23 |
Friedrich Miescher Institute For Biomedical Research |
New screening method for the treatment Friedreich's ataxia
|
EP2924026A1
(en)
|
2014-03-28 |
2015-09-30 |
Novartis Tiergesundheit AG |
Aminosulfonylmethylcyclohexanes as JAK inhibitors
|
WO2016088082A1
(en)
|
2014-12-05 |
2016-06-09 |
Novartis Ag |
Amidomethyl-biaryl derivatives complement factor d inhibitors and uses thereof
|
AU2016236187B2
(en)
|
2015-03-24 |
2020-05-21 |
Helmholtz-Zentrum Fur Infektionsforschung Gmbh |
Inhibitors of Pseudomonas aeruginosa LecB
|
JP6691552B2
(ja)
|
2015-04-30 |
2020-04-28 |
ノバルティス アーゲー |
ファルネソイドx受容体をモジュレートするのに有用である縮合三環式ピラゾール誘導体
|
AU2016308568A1
(en)
|
2015-08-19 |
2018-02-22 |
Vivus Llc |
Pharmaceutical formulations
|
CN105418480B
(zh)
*
|
2015-11-16 |
2019-05-10 |
青岛大学 |
2-(1-(4-氯苯甲酰基)-5-甲氧基-2-甲基-1氢-吲哚-3-基)-n-羟基乙酰胺的制备和应用
|
MA44066A
(fr)
|
2015-12-18 |
2018-10-24 |
Amgen Inc |
Composés sulfonamides de dihydroquinoline d'alcynyle
|
EA038286B1
(ru)
|
2015-12-18 |
2021-08-04 |
Амген Инк. |
Соединения алкилдигидрохинолинсульфонамида
|
PT3579874T
(pt)
|
2017-02-10 |
2021-10-07 |
Novartis Ag |
1-(4-amino-5-bromo-6-(1h-pirazol-1-il)pirimidin-2-il)-1hpirazol- 4-ol e sua utilização no tratamento de cancro
|
AU2018285831A1
(en)
|
2017-06-14 |
2019-12-19 |
European Molecular Biology Laboratory |
Bicyclic heteroaromatic amide compounds for use in therapy
|
AU2018285450A1
(en)
|
2017-06-14 |
2019-12-19 |
European Molecular Biology Laboratory |
Benzofuran ureas or carbamates and heteroaromatic analogues thereof for use in therapy
|
JP2020523379A
(ja)
|
2017-06-14 |
2020-08-06 |
ヨーロピアン モレキュラー バイオロジー ラボラトリーEuropean Molecular Biology Laboratory |
治療への使用のためのベンゾフランアミドおよびそれらの複素芳香族アナログ
|
CA3067070A1
(en)
|
2017-06-14 |
2018-12-20 |
European Molecular Biology Laboratory |
Bicyclic heteroaromatic urea or carbamate compounds for use in therapy
|
BR112020015985A2
(pt)
|
2018-02-06 |
2020-12-15 |
Universität Heidelberg |
Composto, composição farmacêutica e kit
|
WO2019154859A1
(en)
|
2018-02-06 |
2019-08-15 |
Universität Heidelberg |
Fap inhibitor
|
UY38072A
(es)
|
2018-02-07 |
2019-10-01 |
Novartis Ag |
Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
|
GB201811825D0
(en)
|
2018-07-19 |
2018-09-05 |
Benevolentai Bio Ltd |
Organic compounds
|
GB201813791D0
(en)
|
2018-08-23 |
2018-10-10 |
Benevolental Bio Ltd |
Organic compounds
|
MA54550A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Inhibiteurs de kif18a
|
US20220002311A1
(en)
|
2018-12-20 |
2022-01-06 |
Amgen Inc. |
Kif18a inhibitors
|
AU2019404576B2
(en)
|
2018-12-20 |
2025-07-17 |
Amgen Inc. |
Heteroaryl amides useful as KIF18A inhibitors
|
CA3123871A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Kif18a inhibitors
|
EP4007756A1
(en)
|
2019-08-02 |
2022-06-08 |
Amgen Inc. |
Kif18a inhibitors
|
CA3147272A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
CA3147276A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
WO2021026098A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
CN114901362A
(zh)
|
2019-11-05 |
2022-08-12 |
赫姆霍尔兹传染病研究中心有限责任公司 |
针对铜绿假单胞菌生物膜形成的二价leca抑制剂
|
WO2021148805A1
(en)
|
2020-01-22 |
2021-07-29 |
Benevolentai Bio Limited |
Topical pharmaceutical compositions comprising imidazo[1,2-b]pyridazine compounds
|
CA3163585A1
(en)
|
2020-01-22 |
2021-07-29 |
Benevolentai Bio Limited |
Pharmaceutical compositions and their uses
|
CN115667551A
(zh)
|
2020-04-14 |
2023-01-31 |
美国安进公司 |
用于治疗赘生性疾病的kif18a抑制剂
|
WO2021234181A1
(en)
|
2020-05-22 |
2021-11-25 |
Universität Heidelberg |
Use of fap inhibitor in a method of diagnosis
|
US20230227442A1
(en)
|
2020-06-10 |
2023-07-20 |
Amgen Inc. |
Heteroalkyl dihydroquinoline sulfonamide compounds
|
JP2021195367A
(ja)
|
2020-06-10 |
2021-12-27 |
アムジエン・インコーポレーテツド |
シクロプロピルジヒドロキノリンスルホンアミド化合物
|
EP4165024B1
(en)
|
2020-06-10 |
2025-07-16 |
Amgen Inc. |
Cyclobutyl dihydroquinoline sulfonamide compounds
|
WO2022043465A1
(en)
|
2020-08-26 |
2022-03-03 |
Max Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft |
Inhibitors of no production
|
TW202237095A
(zh)
|
2020-12-03 |
2022-10-01 |
德商艾斯巴赫生物有限公司 |
Alc1抑制劑及與parpi之協同性
|
US20220211883A1
(en)
|
2020-12-17 |
2022-07-07 |
Trustees Of Tufts College |
Fap-activated radiotheranostics and uses related thereto
|
CA3234157A1
(en)
|
2021-10-29 |
2023-05-04 |
William M. MENZER |
Inhibitors of viral helicases binding to a novel allosteric binding site
|
WO2023161427A1
(en)
|
2022-02-24 |
2023-08-31 |
Eisbach Bio Gmbh |
Viral combination therapy
|
JP2025515110A
(ja)
|
2022-05-02 |
2025-05-13 |
アイスバッハ・バイオ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Alc1阻害剤の使用およびparpiとの相乗作用
|
WO2024022332A1
(en)
|
2022-07-26 |
2024-02-01 |
Shanghai Sinotau Biotech. Co., Ltd |
Fap inhibitors
|
TW202517632A
(zh)
|
2023-07-12 |
2025-05-01 |
德商Hmnc控股有限公司 |
氘代1,3二氫-2h-吲哚-2-酮衍生物
|
WO2025055943A1
(en)
|
2023-09-12 |
2025-03-20 |
Shanghai Sinotau Biotech. Co., Ltd |
Inhibitors of prostate specific membrane antigen and use thereof
|
WO2025055942A1
(en)
|
2023-09-12 |
2025-03-20 |
Shanghai Sinotau Biotech. Co., Ltd |
Inhibitors of prostate specific membrane antigen and use thereof
|
WO2025088175A1
(en)
|
2023-10-25 |
2025-05-01 |
Eisbach Bio Gmbh |
Alc1 inhibitors for use in treating cancer by potentiating the effects of several classes of approved cancer drugs
|
WO2025088087A1
(en)
|
2023-10-25 |
2025-05-01 |
Eisbach Bio Gmbh |
A pyrido-thieno-pyrimidin derivative as alc1 inhibitor for use in the treatment of homologous recombination deficiency (hrd) cancers
|
WO2025093706A1
(en)
|
2023-10-31 |
2025-05-08 |
Eisbach Bio Gmbh |
Alc1 inhibitors alc1i-1 and alc1i-2 for use in treating pancreatic cancer by potentiating the effect of irinotecan
|